Market Overview:
The global hematology indications related drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hematological disorders, rising geriatric population, and technological advancements in the field of hematology. The global hematology indications related drugs market is segmented on the basis of type into cyclooxygenase inhibitors, antiplatelet agents, thrombin inhibitors, and demethylating agents. On the basis of application, this market is segmented into relieve hematological complications and disease therapy. The North America region dominates this market followed by Europe and Asia Pacific regions respectively.
Product Definition:
Hematology indications are medical conditions that are treated with hematology drugs. Hematology drugs are used to treat blood disorders, cancers of the blood, and other conditions. The importance of hematology indications is that they can be life-threatening if not treated.
Cyclooxygenase Inhibitors:
Cyclooxygenase inhibitors (COX-2) are a group of drugs that inhibit the cyclooxygenase enzyme. This enzyme is responsible for the production of prostaglandins in response to non-specifically injured or damaged cells. Prostaglandins have several functions including pain perception, inflammation, and fever generation.
Antiplatelet Agents:
Antiplatelet agents and its usage in hematology indications related drugs market is expected to witness significant growth over the forecast period. The major factor that propels the growth of this market includes an increase in incidences of cardiovascular diseases globally.
Application Insights:
Based on the application, the global hematology indications related drugs market is segmented into blood disorders, cancer and associated complications, diease therapy indication, and others. The blood disorders segment dominated the overall market in terms of revenue as well as volume in 2017. Increasing prevalence of chronic diseases such as cancer and anemia is expected to be a high rendering driver for this segment over the forecast period.
The diease therapy indication segment is anticipated to witness lucrative growth during the forecast period owing to increasing incidences of chronic conditions such as cardiovascular diseases (CVDs), respiratory problems including asthma and COPD among children along with rising geriatric population across globe which are at risk for these mentioned conditions. This has led pharmaceutical companies including Pfizer Inc., Johnson & Johnson Health System Inc., sanofi aventis Pasteur LLC., Novartis AG., Mylan N.V., etc.
Regional Analysis:
North America dominated the global hematology indications related drugs market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of blood disorders are some factors responsible for its large share. In addition, the high adoption rate of new therapies is also expected to drive this regional market over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure in emerging countries such as China and India.
Growth Factors:
- Increasing incidence of blood disorders and cancer
- Growing demand for targeted therapies
- Rising awareness about hematology indications related drugs among patients and healthcare professionals
- Technological advancements in the field of hematology indications related drugs development and manufacturing
- Availability of government funding for research on hematology indications related drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Hematology Indications Related Drugs Market Research Report
By Type
Cyclooxygenase Inhibitors, Antiplatelet Agents, Thrombin Inhibitors, Demethylating Agents
By Application
Relieve Hematological Complications, Diease Thearpy
By Companies
Gilead, Bayer, Owkin, Amgen, Alexion Pharmaceuticals, AllCells, LLC, Kiadis Pharma, Bicycle Therapeutics, Rennova Health, Sierra Oncology, Spectrum Pharmaceuticals, Inc., Astex Therapeutics, Nucentra, Novo A/S
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Hematology Indications Related Drugs Market Report Segments:
The global Hematology Indications Related Drugs market is segmented on the basis of:
Types
Cyclooxygenase Inhibitors, Antiplatelet Agents, Thrombin Inhibitors, Demethylating Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Relieve Hematological Complications, Diease Thearpy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead
- Bayer
- Owkin
- Amgen
- Alexion Pharmaceuticals
- AllCells, LLC
- Kiadis Pharma
- Bicycle Therapeutics
- Rennova Health
- Sierra Oncology
- Spectrum Pharmaceuticals, Inc.
- Astex Therapeutics
- Nucentra
- Novo A/S
Highlights of The Hematology Indications Related Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cyclooxygenase Inhibitors
- Antiplatelet Agents
- Thrombin Inhibitors
- Demethylating Agents
- By Application:
- Relieve Hematological Complications
- Diease Thearpy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hematology Indications Related Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hematology indications related drugs are medications used to treat blood disorders. These medications can help to improve the quality of blood, reduce the risk of infection, and speed up the healing process.
Some of the major companies in the hematology indications related drugs market are Gilead, Bayer, Owkin, Amgen, Alexion Pharmaceuticals, AllCells, LLC, Kiadis Pharma, Bicycle Therapeutics, Rennova Health, Sierra Oncology, Spectrum Pharmaceuticals, Inc., Astex Therapeutics, Nucentra, Novo A/S.
The hematology indications related drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hematology Indications Related Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hematology Indications Related Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hematology Indications Related Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hematology Indications Related Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hematology Indications Related Drugs Market Size & Forecast, 2020-2028
4.5.1 Hematology Indications Related Drugs Market Size and Y-o-Y Growth
4.5.2 Hematology Indications Related Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cyclooxygenase Inhibitors
5.2.2 Antiplatelet Agents
5.2.3 Thrombin Inhibitors
5.2.4 Demethylating Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Relieve Hematological Complications
6.2.2 Diease Thearpy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hematology Indications Related Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hematology Indications Related Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cyclooxygenase Inhibitors
9.6.2 Antiplatelet Agents
9.6.3 Thrombin Inhibitors
9.6.4 Demethylating Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Relieve Hematological Complications
9.10.2 Diease Thearpy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cyclooxygenase Inhibitors
10.6.2 Antiplatelet Agents
10.6.3 Thrombin Inhibitors
10.6.4 Demethylating Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Relieve Hematological Complications
10.10.2 Diease Thearpy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cyclooxygenase Inhibitors
11.6.2 Antiplatelet Agents
11.6.3 Thrombin Inhibitors
11.6.4 Demethylating Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Relieve Hematological Complications
11.10.2 Diease Thearpy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cyclooxygenase Inhibitors
12.6.2 Antiplatelet Agents
12.6.3 Thrombin Inhibitors
12.6.4 Demethylating Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Relieve Hematological Complications
12.10.2 Diease Thearpy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cyclooxygenase Inhibitors
13.6.2 Antiplatelet Agents
13.6.3 Thrombin Inhibitors
13.6.4 Demethylating Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Relieve Hematological Complications
13.10.2 Diease Thearpy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hematology Indications Related Drugs Market: Competitive Dashboard
14.2 Global Hematology Indications Related Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead
14.3.2 Bayer
14.3.3 Owkin
14.3.4 Amgen
14.3.5 Alexion Pharmaceuticals
14.3.6 AllCells, LLC
14.3.7 Kiadis Pharma
14.3.8 Bicycle Therapeutics
14.3.9 Rennova Health
14.3.10 Sierra Oncology
14.3.11 Spectrum Pharmaceuticals, Inc.
14.3.12 Astex Therapeutics
14.3.13 Nucentra
14.3.14 Novo A/S
